Clinical Study of HRS-2129 for Acute Gouty Arthritis
Key facts
- Where
- Guangzhou and Nanjing, ChinaSee the 2 sites
- Phase
- Phase 2
Where in China
- The Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, ChinaContact: Yunfeng Pan (principal investigator)Taking people
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical SchoolNanjing, ChinaContact: Lingyun Sun (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shandong Suncadia Medicine Co., Ltd.
- Trial code
- NCT07706777
- Record updated
- 3 September 2026
- Original description
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.Read full original descriptionShow less
Clinical Study on Safety and Efficacy of HRS-2129 for Acute Gouty Arthritis
The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.
Inclusion: Able and willing to provide a written informed consent; Subjects requiring Acute gouty arthritis; Target joint VAS pain score ≥ 50 mm (screening).
Exclusion: Subjects with a history of severe allergies; Subjects with nervous system disease; Subjects with a history of mental illness; History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s); The investigators determined that other conditions were inappropriate for participation in this clinical trial; QTc：>450ms（male），>470ms（female）; Subjects with abnormal liver and renal function; Subjects with poorly controlled hypertensive.